6,531 results match your criteria Acta haematologica[Journal]


Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Acta Haematol 2020 May 19:1-8. Epub 2020 May 19.

Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada,

Background: Allogeneic hematopoietic cell transplantation (HCT) is curative for high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but with significant non-relapse mortality (NRM) and relapse. We compared the combination of anti-thymocyte globulin (ATG; 4.5 mg/kg) and post-transplant cyclophosphamide (PTCy; 50 mg/kg on day +3 and +4) with other graft-versus-host disease (GvHD) prophylaxis regimens used for these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507536DOI Listing

The Association between Metabolic Syndrome and Multiple Myeloma.

Acta Haematol 2020 May 14:1-9. Epub 2020 May 14.

Department of Chemical Pathology, Guy's and St Thomas' and Lewisham and Greenwich Trust, London, United Kingdom,

Multiple myeloma (MM) is a haematological malignancy arising from monoclonal proliferation of plasma cells in the bone marrow, resulting in the presence of paraproteins or M-protein in serum. The involvement of paraproteins produced by malignant plasma cells in the development of hyperlipidaemia and low-HDL cholesterol has been described, as has an association with MM and obesity, hypertension, and type 2 diabetes mellitus, and insulin resistance, that is, features of the metabolic syndrome (MS). There is an association between MS components, inflammatory cytokines, and the development of MM, and some drugs used in the treatment of MS such as statins and metformin may improve outcomes in MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505992DOI Listing

Cardiac Care of Patients with Cardiac Amyloidosis.

Acta Haematol 2020 May 14:1-9. Epub 2020 May 14.

Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel.

Cardiac amyloidosis, the majority of cases of which are due to immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR), affects different aspects of the heart and cardiovascular system. Amyloid-induced cardiomyopathy, clinically manifesting with heart failure and electrophysiological abnormalities, has distinct characteristics compared to non-amyloid cardiomyopathies. Accordingly, specific management strategies are required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506919DOI Listing

Chronic Pain Does Not Impact Baseline Circulating Cytokine Levels in Adults with Sickle Cell Disease.

Acta Haematol 2020 May 13:1-6. Epub 2020 May 13.

Medical Sciences Institute, Versiti, Milwaukee, Wisconsin, USA.

Chronic pain affects 50% of adults with sickle cell disease (SCD). Although inflammation is thought to contribute to the pathogenesis of chronic pain, no studies have examined the differences in circulating cytokines between patients with SCD with and without chronic pain. We performed an observational cohort study using blood and urine samples from adults with SCD with and without chronic pain at their usual state of health. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507563DOI Listing

Peculiar Congenital Factor VII Defect with the Proposita and Her Mother Showing the Same Compound Heterozygosity for Thr384Met and Arg413Gln.

Acta Haematol 2020 May 12:1-5. Epub 2020 May 12.

Bioquimica Clinica, Universidad Fasta, Mar del Plata, Argentina.

Objective: To investigate a family with factor VII (FVII) deficiency from Argentina.

Patients And Methods: The proposita is a 14-year-old girl who presented with a mild to moderate bleeding tendency. Menorrhagia is controlled with periodical administration of small doses of recombinant FVII concentrate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507071DOI Listing

Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?

Acta Haematol 2020 May 12:1-8. Epub 2020 May 12.

Cardiology Department, Rabin Medical Center, Petah Tikva, Israel.

Coronavirus disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is responsible for the ongoing 2019-2020 pandemic. Venous thromboembolism (VTE), a frequent cardiovascular and/or respiratory complication among hospitalized patients, is one of the known sequelae of the illness. Hospitalized COVID-19 patients are often elderly, immobile, and show signs of coagulopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508233DOI Listing

Authors:

Acta Haematol 2020 May 11;143(3):189. Epub 2020 May 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508547DOI Listing

T-Cell Prolymphocytic Leukemia: Long-Term Remissions Challenging!

Authors:
Leopold Sellner

Acta Haematol 2020 May 11:1-2. Epub 2020 May 11.

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507469DOI Listing

Treating Leukemia in the Time of COVID-19.

Acta Haematol 2020 May 11:1-13. Epub 2020 May 11.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA,

The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to the management of patients with leukemia. The biology of each leukemia and its corresponding treatment with conventional intensive chemotherapy, with or without targeted therapies (venetoclax, FLT3 inhibitors, IDH1/2 inhibitors, Bruton's tyrosine kinase inhibitors), introduce additional layers of complexity during COVID-19 high-risk periods. The knowledge about COVID-19 is accumulating rapidly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508199DOI Listing
May 2020
0.994 Impact Factor

Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report.

Acta Haematol 2020 May 11:1-4. Epub 2020 May 11.

Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy,

There is an unmet clinical need for elderly or unfit diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplantation. Lenalidomide is an immunomodulatory agent with antitumor activity in non-Hodgkin lymphoma, with an acceptable toxicity profile and manageable side effects. A 79-year-old Caucasian male with non-germinal center B-cell-like DLBCL achieved complete remission (CR) after first-line treatment with seven out of eight scheduled cycles of a polychemotherapy containing anthracycline, which had to be discontinued early due to the onset of atrial fibrillation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505716DOI Listing

The Pathology of Amyloidosis in Classification: A Review.

Authors:
Maria M Picken

Acta Haematol 2020 May 11:1-13. Epub 2020 May 11.

Department of Pathology, Loyola University Medical Center, Maywood, Illinois, USA,

Background: The amyloidoses are a rare and heterogeneous group of disorders that are characterized by the deposition of abnormally folded proteins in tissues ultimately leading to organ damage. The deposits are mainly extracellular and are recognizable by their affinity for Congo red and their yellow-green birefringence under polarized light. Current classification of amyloid in medical practice is based on the amyloid protein type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506696DOI Listing

Perspective: SARS-CoV-2, COVID-19 and Haematologists.

Acta Haematol 2020 May 6:1-4. Epub 2020 May 6.

Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508021DOI Listing

What to Look Out for when Transplanting T-Cell Prolymphocytic Leukemia.

Acta Haematol 2020 May 5:1-3. Epub 2020 May 5.

Department I of Internal Medicine, Center for Integrated Oncology (CIO), Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, Cologne, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507415DOI Listing

Conventional Therapy for Amyloid Light-Chain Amyloidosis.

Acta Haematol 2020 Apr 30:1-8. Epub 2020 Apr 30.

Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy,

The vast majority of patients with light-chain (AL) amyloidosis are not eligible for stem cell transplant and are treated with conventional chemotherapy. Conventional regimens are based on various combinations of dexamethasone, alkylating agents, proteasome inhibitors, and immunomodulatory drugs. The choice of these regimens requires a careful risk stratification, based on the extent of amyloid organ involvement, comorbidities, and the characteristics of the amyloidogenic plasma cell clone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507072DOI Listing

Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia.

Acta Haematol 2020 Apr 29:1-5. Epub 2020 Apr 29.

University of California Davis Comprehensive Cancer Center, Sacramento, California, USA.

T-cell large granular lymphocyte (LGL) leukemia is a rare indolent neoplasm primarily treated with immunosuppression. Few therapies and no consensus exist for the optimal treatment of T-cell LGL leukemia refractory to immunosuppressive therapy. Here, we report a case of relapsed/refractory T-cell LGL treated with belinostat. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506918DOI Listing

When to Suspect a Diagnosis of Amyloidosis.

Acta Haematol 2020 Apr 27:1-8. Epub 2020 Apr 27.

Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA,

Amyloidosis is a group of complex diseases caused by extracellular deposition of pathological insoluble fibrillary protein in organs and tissues and may result in severe organ dysfunction. Despite the etiological heterogeneity of systemic amyloidosis, the clinical manifestations of the different forms of amyloidosis largely overlap and depend upon the effected organ. The signs and symptoms that should raise suspicion for the potential diagnosis of amyloidosis are usually nonspecific; therefore, establishing the diagnosis is difficult, and early diagnosis requires clinical suspicion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506617DOI Listing

A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.

Acta Haematol 2020 Apr 23:1-8. Epub 2020 Apr 23.

R.M. Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation.

Introduction: This prospective study evaluated a calcineurin inhibitor-free graft-versus-host disease (GVHD) prophylaxis regimen of ruxolitinib in combination with post-transplant cyclophosphamide (PTCy). Patents and Methods: Twenty patients with primary or secondary myelofibrosis were prospectively enrolled. Reduced intensity conditioning was performed, followed by allogeneic stem cell transplantation from related (n = 7) or unrelated (n = 13) donors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506758DOI Listing

Multiple Myeloma in the Time of COVID-19.

Acta Haematol 2020 Apr 17:1-7. Epub 2020 Apr 17.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA,

We provide our recommendations (not evidence based) for managing multiple myeloma patients during the pandemic of COVID-19. We do not recommend therapy for smoldering myeloma patients (standard or high risk). Screening for COVID-19 should be done in all patients before therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507690DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206354PMC

Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.

Acta Haematol 2020 Apr 14:1-7. Epub 2020 Apr 14.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes. Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in preclinical studies. However, clinical activity of venetoclax and TKI-based regimens is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506346DOI Listing
April 2020
0.994 Impact Factor

Genetic Analysis of Afibrinogenemia and Hypofibrinogenemia: Novel Mutations in the FGB Gene in the Turkish Population.

Acta Haematol 2020 Apr 14:1-4. Epub 2020 Apr 14.

Pediatrics Department, TOBB Economy and Technical University Hospital, Ankara, Turkey.

Introduction: Congenital afibrinogenemia is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Hypofibrinogenemia is characterized by fibrinogen levels <1.5 g/L. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505174DOI Listing

Integrative Analysis of Long Noncoding RNAs in Patients with Graft-versus-Host Disease.

Acta Haematol 2020 Apr 14:1-19. Epub 2020 Apr 14.

Medical School, Nankai University, Tianjin, China,

Background: Chronic graft-versus-host disease (cGVHD) remains a major cause of late non-recurrence mortality despite remarkable improvements in the field of allogeneic hematopoietic stem cell transplantation. Although recent studies have found that B-cell receptor (BCR)-activated B cells contribute to pathogenesis in cGVHD, the specific molecular mechanisms of B cells in this process remain unclear.

Methods: In our study, human long noncoding RNA (lncRNA) microarrays and bioinformatic analysis were performed to identify different expressions of lncRNAs in peripheral blood B cells from cGVHD patients compared with healthy ones. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505255DOI Listing
April 2020
0.994 Impact Factor

Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.

Acta Haematol 2020 Apr 7:1-6. Epub 2020 Apr 7.

Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), Göttingen, Germany.

Initial treatment with the monoclonal anti-CD52 antibody alemtuzumab induces responses in the majority of patients with T-cell prolymphocytic leukemia (T-PLL). In eligible patients, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an option to consolidate hematological remissions. Here, we report our experience with 10 patients who received allo-HSCT against T-PLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506302DOI Listing

High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis.

Acta Haematol 2020 Apr 3:1-7. Epub 2020 Apr 3.

Amyloidosis Center, Boston University School of Medicine and Stem Cell Transplantation Program of Section of Hematology and Oncology, Boston Medical Center, Boston, Massachusetts, USA,

AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High-dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in myeloma. This application has evolved significantly over the past three decades. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506498DOI Listing

Supportive Care in AL Amyloidosis.

Acta Haematol 2020 Apr 1:1-8. Epub 2020 Apr 1.

Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.

Immunoglobulin light-chain (AL) amyloidosis is a systemic disease characterized by the production and deposition of light chain-derived amyloid fibrils in different organs. Prompt treatment directed to the underlying plasma cell clone is crucial in order to achieve a rapid, deep and durable hematologic response. The decrease in the production of the amyloidogenic light chains is a required condition to obtain the organ response, which is commonly delayed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506760DOI Listing

Desensitization in Iron Product Allergy.

Acta Haematol 2020 Mar 17:1-4. Epub 2020 Mar 17.

Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari-Aldo Moro, Bari, Italy,

Iron deficiency is the main cause of anemia in both sexes, with women being more commonly affected. Iron therapy is currently considered an effective and safe remedy to replenish the iron storages. Iron can be administrated both orally and intravenously. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503768DOI Listing

Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.

Acta Haematol 2020 Mar 11:1-9. Epub 2020 Mar 11.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Treatment options are limited for patients with advanced forms of myeloproliferative neoplasms (MPN) including blast-phase disease (MPN-BP). Decitabine has frequently been deployed but its efficacy and safety profile are not well described in this population. We retrospectively reviewed 42 patients treated with decitabine either alone or in combination with ruxolitinib at our institution: 16 with MPN-BP, 14 with MPN accelerated-phase (MPN-AP), and 12 with myelofibrosis with high-risk features (MF-HR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506146DOI Listing

Treating Plasma Cell Myeloma in Developing Countries: Does Everyone Need the Newest Drugs?

Acta Haematol 2020 Mar 10:1-3. Epub 2020 Mar 10.

Centre forHaematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505991DOI Listing

A Unique Case of Acquired Hemophilia A Presenting with Transient Ischemic Attack.

Acta Haematol 2020 Mar 10:1-3. Epub 2020 Mar 10.

Division of Angiology and Haemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland,

Acquired hemophilia A (AHA) is a rare but serious condition, usually associated with significant spontaneous or traumatic bleeding and a high mortality rate. In this report, we describe the case of an elderly patient presenting a transient ischemic attack concurrently with AHA. A thrombotic event in AHA is occasionally associated with the use of bypassing agents for treatment, but a spontaneous thrombotic event has not ever been described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506273DOI Listing

Noonan Syndrome and Acute Myeloid Leukemia in Adults: The Importance of a Correct Multidisciplinary Approach during Childhood.

Authors:
Fabio Timeus

Acta Haematol 2020 Mar 10:1-2. Epub 2020 Mar 10.

Department of Pediatrics, Chivasso Hospital, Turin, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506388DOI Listing

The Prognostic Role of Lactate Dehydrogenase at First Relapse of Multiple Myeloma.

Acta Haematol 2020 Feb 26:1-2. Epub 2020 Feb 26.

Division of Hematology, Department of Medicine, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506174DOI Listing
February 2020

The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.

Acta Haematol 2020 Feb 19:1-9. Epub 2020 Feb 19.

Department of Oncology, First People's Hospital of Lanzhou City, Lanzhou, China.

MYC, as a powerful transcription factor, plays a vital role in various cancers. The clinical significance of MYC alterations in diffuse large B-cell lymphoma (DLBCL) has been investigated for a long time. In this study, we comprehensively summarize the different alterations of MYC in DLBCL, including MYC overexpression, MYC translocations, MYC mutations, and increased gene copy number of MYC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505892DOI Listing
February 2020

WhatsApp in Acta Haematologica?

Authors:
Pia Raanani

Acta Haematol 2020 Feb 12. Epub 2020 Feb 12.

Hematology Division, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505947DOI Listing
February 2020

Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data from a Single Institution.

Acta Haematol 2020 Feb 11:1-7. Epub 2020 Feb 11.

Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico,

Background: The treatment of patients with multiple myeloma (MM) has evolved in recent years, and the disease-associated prognosis has improved substantially. This improvement has been driven largely by the approval of novel agents, many of which are expensive and not universally available. Less expensive but effective approaches would be of value globally. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505606DOI Listing
February 2020
0.994 Impact Factor

Combined Congenital Hypodysfibrinogemia and Factor XI Deficiency in a Chinese Family.

Acta Haematol 2020 Jan 24:1-6. Epub 2020 Jan 24.

Department of Medical Laboratory, First Affiliated Hospital of Nanchang University, Nanchang, China,

Both congenital hypodysfibrinogenemia and factor XI deficiency are rare coagulopathies caused by mutations within the fibrinogen and F11 genes, respectively. To investigate the pathogenesis of combined congenital hypodysfibrinogenemia with factor XI (FXI) deficiency in a Chinese family, coagulation assays, FXI activity (the 1-stage method), fibrinogen activity (the Clauss method), and antigen (prothrombin time [PT]-derived method) were performed. The sequences of fibrinogen genes and F11 were amplified by PCR and analyzed by direct sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505012DOI Listing
January 2020

Coexistence of Pure Red Cell Aplasia and Autoimmune Haemolytic Anaemia Associated with Thymoma.

Acta Haematol 2020 Jan 21:1-5. Epub 2020 Jan 21.

Department of Haematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Thymoma is an uncommon neoplasia derived from the epithelial cells of the thymus, which leads to immune dysregulation and is associated with a series of autoimmune diseases. However, the concurrence of these disease entities is rare, and the exact mechanisms of these diseases are still unclear. We have admitted several cases who were diagnosed with thymoma, autoimmune haemolytic anaemia, and pure red cell aplasia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503376DOI Listing
January 2020
0.994 Impact Factor

Alpha-Thalassemia Carrier due to -α3.7 Deletion: Not So Silent.

Acta Haematol 2020 Jan 14:1-6. Epub 2020 Jan 14.

Department of Hematology-Oncology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel,

Background/objective: Alpha-thalassemia is one of the most prevalent genetic diseases, with the -α3.7 deletion being the most common mutation. Molecular studies have suggested mechanisms to explain the mild phenotype of "silent carrier" heterozygotes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503023DOI Listing
January 2020

Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?

Acta Haematol 2020 Jan 9:1-2. Epub 2020 Jan 9.

Unit of Blood Diseases and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, Spedali Civili of Brescia, University of Brescia, Brescia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505088DOI Listing
January 2020

Impact of Platelet Counts, Surgical Methods, and Preoperative Platelet Transfusion on the Outcome of Splenectomy for Immune Thrombocytopenia.

Acta Haematol 2020 Jan 7:1-7. Epub 2020 Jan 7.

School of Medicine, Chang Gung University, Taoyuan, Taiwan.

Introduction: Splenectomy is an important and potentially curative treatment for immune thrombocytopenia (ITP). Laparoscopic splenectomy (LS) has replaced open splenectomy (OS) as the standard approach. The prognostic role of platelet count and the clinical indication of preoperative platelet transfusion are not entirely clear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505011DOI Listing
January 2020

Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis.

Acta Haematol 2020 Jan 2:1-4. Epub 2020 Jan 2.

Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Immunoglobulin light-chain amyloidosis (AL) is a disease with limited treatment options due to the frailty of patients caused by organ damage. Since the clonal plasma cells often contain the cytogenetic aberration t(11;14), the Bcl-2 inhibitor venetoclax is suggested to have a role in the treatment of AL. Here, we report of a heart-transplanted patient, refractory to multiple therapies, reaching a rapid complete response with single-agent venetoclax. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504355DOI Listing
January 2020

Avoiding the Thorns of the Gifted Red Rose: Case Report of Late Diagnosis of Polycythemia Rubra Vera in a Sibling Bone Marrow Transplantation Donor for a Patient with Chronic Myeloid Leukemia.

Acta Haematol 2019 Dec 18:1-2. Epub 2019 Dec 18.

Allogeneic Blood and Marrow Transplant Service, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504740DOI Listing
December 2019

Hemophilia A in Females: Considerations for Clinical Management.

Acta Haematol 2019 Dec 11:1-6. Epub 2019 Dec 11.

Banner MD Anderson Cancer Center, Gilbert, Arizona, USA,

Approximately 50% of female carriers of hemophilia A have factor VIII (FVIII) levels below 0.5 IU/dL and may be categorized as having mild hemophilia. Females with hemophilia may go undiagnosed for years because the most common symptoms - menorrhagia and bleeding after childbirth - also occur in females without hemophilia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503889DOI Listing
December 2019

Risk Factors for Acute Kidney Injury and Chronic Kidney Disease following Allogeneic Hematopoietic Stem Cell Transplantation for Hematopoietic Malignancies.

Acta Haematol 2019 Dec 10:1-13. Epub 2019 Dec 10.

Department of Hematology, Nippon Medical School, Tokyo, Japan.

Background: Acute kidney injury (AKI) and chronic kidney disease (CKD) are considered common complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Objectives And Method: In this study, 114 patients who had undergone allo-HSCT were retrospectively analyzed to investigate the risk factors for onset of posttransplant AKI and CKD as defined by the new Kidney Disease Improving Global Outcomes criteria.

Results: Seventy-four patients (64. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504354DOI Listing
December 2019

Kidney Disease after Allogeneic Hematopoietic Cell Transplantation: In Search of the Truth.

Acta Haematol 2019 Dec 3:1-2. Epub 2019 Dec 3.

BMT Unit, Hematology Department, G. Papanicolaou Hospital, Thessaloniki, Greece,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504523DOI Listing
December 2019

Reexamining 1-Gene Deletion α-Thalassemia: Is the Silent Carrier of Clinical Significance?

Acta Haematol 2019 Nov 27:1-2. Epub 2019 Nov 27.

Department of Pediatrics, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, New York, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504281DOI Listing
November 2019

Extended Follow-up of an Educational Intervention Encouraging Appropriate Use of Blood Transfusions.

Acta Haematol 2019 Nov 21:1-6. Epub 2019 Nov 21.

Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.

Introduction: A restrictive transfusion strategy of packed red blood cells (PRBCs) has been associated with at least non-inferior patient outcomes in a variety of clinical settings. In December 2014, we conducted an educational intervention which consisted of an oral presentation and computerized notifications at a single tertiary medical center.

Objective: The aim of this study was to examine the long-term effects of a simple and low-cost educational intervention aimed to promote awareness to transfusion guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503988DOI Listing
November 2019

FLAG and Etoposide as Salvage Treatment in Acute Myeloid Leukemia.

Acta Haematol 2019 Nov 21:1-2. Epub 2019 Nov 21.

Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504379DOI Listing
November 2019

Weekly Cyclophosphamide-Bortezomib-Dexamethasone Induction Performs Comparably to Twice-Weekly Dosing with Respect to Both Response Rates and Survival after Autologous Transplant.

Acta Haematol 2019 Nov 5:1-2. Epub 2019 Nov 5.

Department of Haematology, Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501791DOI Listing
November 2019

A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia.

Acta Haematol 2019 Oct 30:1-6. Epub 2019 Oct 30.

Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA.

The combination of rituximab, cyclophosphamide, and dexamethasone (RCD) is highly effective in the treatment of warm autoimmune hemolytic anemia (WAIHA) associated with chronic lymphocytic leukemia (CLL). We treated a cohort of patients with relapsed/refractory WAIHA, without CLL, with RCD. The primary objective was to evaluate the overall response (OR) of RCD therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501538DOI Listing
October 2019